Cardamonin Attenuates Inflammation and Oxidative Stress in Interleukin-1β-Stimulated Osteoarthritis Chondrocyte through the Nrf2 Pathway
Open Access
- 27 May 2021
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 10 (6) , 862
Abstract
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by the deterioration of articular cartilage. The progression of OA leads to an increase in inflammatory mediators in the joints, thereby promoting the destruction of the cartilage matrix. Recent studies have reported on the anti-inflammatory and antioxidant properties of cardamonin, which also appears to interact with cellular targets, such as nuclear erythroid 2-related factor 2 (Nrf2), extracellular signal-regulated kinase (ERK), and mammalian target of rapamycin (mTOR) during the progression of tumors. To date, few studies have investigated the effects of cardamonin on chondrocyte inflammation. In the current study, we determined that treating interleukin-1 beta (IL-1β-stimulated chondrocyte cells) with cardamonin significantly reduced the release of nitric oxide (NO) and prostaglandin E2 (PGE2) and significantly inhibited the expression of pro-inflammatory proteins, including inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2). Cardamonin was also shown to: (1) inhibit the activation and production of matrix metalloproteinases (MMPs), (2) suppress the nuclear factor-κB (NF-κB) signaling pathway, (3) suppress the expression of toll-like receptor proteins, (4) activate the Nrf2 signaling pathway, and (5) increase the levels of antioxidant proteins heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1). The increase in antioxidant proteins led to corresponding antioxidant effects (which were abolished by Nrf2 siRNA). Our findings identify cardamonin as a candidate Nrf2 activator for the treatment and prevention of OA related to inflammation and oxidative stress.Keywords
Funding Information
- Ministry of Science and Technology (MOST 107-2314-B-038-088, MOST108-2314-B-038-082)
- National Defense Medical Center (ATSGH-C107-211, TSGH-C107-081, TSGH-108-089, TSGH-C108-113, TSGH-D-10902, TSGH-E-110232)
- Medical Affairs Bureau (MAB-106-006)
This publication has 30 references indexed in Scilit:
- The Role of Changes in Extracellular Matrix of Cartilage in the Presence of Inflammation on the Pathology of OsteoarthritisBioMed Research International, 2013
- MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation – divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradationOsteoarthritis and Cartilage, 2010
- Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing:In vivoandin vitroevidenceExpert Opinion on Investigational Drugs, 2009
- Cartilage in normal and osteoarthritis conditionsBest Practice & Research Clinical Rheumatology, 2008
- Heme oxygenase-1–derived carbon monoxide enhances the host defense response to microbial sepsis in miceJournal of Clinical Investigation, 2008
- Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-κB nuclear translocation and Iκ-B phosphorylation in RAW 264.7 macrophage cellsMolecular Immunology, 2007
- Osteoarthritis of the knee – clinical assessments and inflammatory markersOsteoarthritis and Cartilage, 2004
- Induction of matrix metalloproteinase-13 gene expression by TNF-α is mediated by MAP kinases, AP-1, and NF-κB transcription factors in articular chondrocytesExperimental Cell Research, 2003
- IL‐1β induces COX2, MMP‐1, ‐3 and ‐13, ADAMTS‐4, IL‐1β and IL‐6 in human tendon cellsJournal of Orthopaedic Research, 2003
- KNEE PAIN AND DISABILITY IN THE COMMUNITYRheumatology, 1992